Taken together, our research demonstrates a novel anti(lymph)angiogenic compound that selectively targets VEGFR-3, modulates the TME to induce tumor blood vessel homogenization (i.e., leaving fewer and overall larger vessels), and enhances immunotherapy. Here, FLT4 is linked to neoplasm.